多发性骨髓瘤
MEK抑制剂
癌症研究
对偶(语法数字)
医学
化学
内科学
MAPK/ERK通路
磷酸化
生物化学
艺术
文学类
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2020-11-13
卷期号:11 (1): 5-6
被引量:8
标识
DOI:10.1158/2159-8290.cd-nb2020-101
摘要
According to preliminary results from a phase I trial, VS-6766, also known as CH5126766, a first-in-class dual RAF-MEK inhibitor, is safe and has shown some efficacy in solid tumors and multiple myeloma harboring various RAS-RAF mutations.
科研通智能强力驱动
Strongly Powered by AbleSci AI